* ] The following portion has been omitted pursuant to a Confidential Treatment Request under Rule 24b-2 of the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.Peregrine Pharmaceuticals Inc • September 9th, 2008 • In vitro & in vivo diagnostic substances
This contract is awarded as a result of Medical Science and Technology (S&T) Chemical and Biological Defense Transformational Medical Technologies Initiative (TMTI) BAA HDTRA1-07-TMTI-BAA.
